跳至主要内容
临床试验/IRCT20190810044500N4
IRCT20190810044500N4招募中2 期

Evaluation of therapeutic effects of Crocin in reducing progression of diabetic nephropathy: A randomized triple-blind placebo-controlled trial

Yazd University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • age 18 years or older
  • A history of type 2 diabetes for at least 5 years, as defined by the WHO
  • fasting urine albumin/creatinine ratio of 30 mg/g or higher on two separate occasions within the past 3 months
  • HbA1C less than 8
  • blood pressure less than 160/100
  • Serum creatinine levels less than or equal to 2 mg/dL
  • treatment of hyperglycemia with (but not limited to) an oral hypoglycemic agent or insulin
  • treatment of hypercholesterolemia with(but not limited to) a statin

排除标准

  • GFR less than 30 mL/min/1.73 m2
  • chronic heartfailure with New York Heart Association class III or IV
  • alcohol dependency or cigarette smoking
  • use of one of certain specified medications within 3 months prior to enrollment in the study (nonsteroidal anti-inflammatory agents and antioxidant supplements, including vitamin E, vitamin C, fish oil extracts [omega-3 fatty acids], green tea preparations, pomegranate extracts, and grape extracts
  • Recent stroke, active cancer, anemia
  • recurrent urinary tract infection
  • pregnancy and lactation
  • Drug intolerance
  • Serious medical conditions in which the patient is unable to attend regular visits include severe cardiovascular disease such as angina or heart attack.
  • Mental conditions that prevent conscious consent to enter the study or follow the study protocol

研究者

发起方
Yazd University of Medical Sciences

相似试验